TacticScaleWhat IQVIA Does & How It Makes Money (IQV)
Updated October 2026 · reflects IQVIA's latest reported financials
Clinical research, data, and analytics partner to drug and healthcare companies. It earns service fees from life sciences companies to run and support clinical trials and lab work.
How IQVIA makes money
It earns service fees from life sciences companies to run and support clinical trials and lab work. It also earns revenue from cloud software, healthcare data and analytics, consulting, and outsourced sales and medical engagement services.
What IQVIA does
IQVIA Holdings is a major services and data provider to the life sciences industry. Its customers include pharmaceutical, biotechnology, device and diagnostic, and consumer health companies across the Americas, Europe, Africa, and Asia-Pacific. The company was formerly Quintiles IMS Holdings, took the IQVIA name in November 2017, and is based in Durham, North Carolina. It has three segments. Research & Development Solutions runs clinical trials, from study design and site monitoring to central, genomic, bioanalytical, vaccine, and biomarker lab services. Technology & Analytics Solutions sells cloud applications, real world evidence tools, consulting, and detailed data on drug sales and prescribing down to the individual prescriber. Contract Sales & Medical Solutions provides outsourced engagement with healthcare providers and patients, plus medical and scientific strategy services. It also has a strategic collaboration with Kexing Biopharm on biosimilar development.
Products & services
- Clinical trial management and monitoring (CRO services)
- Central, genomic, bioanalytical and biomarker laboratory services
- Real world evidence solutions
- Cloud-based life sciences applications
- Pharmaceutical sales and prescribing data metrics
- Contract sales and medical engagement services
What is IQVIA worth?
On an owner-earnings DCF, IQVIA's most-likely value is about $255 versus a recent price near $260 (2% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$132) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 6.4× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Quest Diagnostics (DGX) · IDEXX Laboratories (IDXX) · Veeva Systems (VEEV) · QuidelOrtho (QDEL) · Labcorp (LH)